JGC
EIGR

J. Goldman & Co’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

J. Goldman & Co’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,002
Closed -$2.86M – 366
2020
Q1 		$2.86M Buy
14,002
+12,486
+824% +$3.98M 0.34% 75
2019
Q4 		$677K Buy
+1,516
New +$538K 0.05% 205

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

J. Goldman & Co's EIGR Position: Q2 2020 in Review

J. Goldman & Co sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 14,002 shares — an estimated $2.86M sold.

J. Goldman & Co first reported a position in EIGR in Q4 2019 and held it in 2 quarters. The position peaked at $2.86M in Q1 2020. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

  • J. Goldman & Co reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • J. Goldman & Co sold 14,002 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $2.86M.
  • J. Goldman & Co first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • J. Goldman & Co's Eiger BioPharmaceuticals, Inc. position peaked at $2.86M in Q1 2020.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on J. Goldman & Co's 13F filing for Q2 2020, filed 14 Aug 2020.